These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33506768)

  • 1. IO + IO = More to Know:: The Uncertain Potential for Combined Interventional and Immuno-Oncology.
    Brown DB; Agarwal R
    J Vasc Interv Radiol; 2021 Feb; 32(2):196-197. PubMed ID: 33506768
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolution of interventional oncology in the 21st century.
    Helmberger T
    Br J Radiol; 2020 Sep; 93(1113):20200112. PubMed ID: 32706978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions.
    Cole S; Zibelman M; Bertino E; Yucebay F; Reynolds K
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():96-104. PubMed ID: 31099682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design and identification of immuno-oncology drug combinations.
    Iafolla MAJ; Selby H; Warner K; Ohashi PS; Haibe-Kains B; Siu LL
    Eur J Cancer; 2018 May; 95():38-51. PubMed ID: 29631102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.
    Tsimberidou AM; Levit LA; Schilsky RL; Averbuch SD; Chen D; Kirkwood JM; McShane LM; Sharon E; Mileham KF; Postow MA
    J Immunother Cancer; 2018 Oct; 6(1):108. PubMed ID: 30340549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immuno-oncology and interventional oncology: a winning combination. The latest scientific evidence.
    Lucatelli P; Iezzi R; De Rubeis G; Goldberg SN; Bilbao JI; Sami A; Akhan O; Giuliante F; Pompili M; Tagliaferri L; Valentini V; Gasbarrini A; Colosimo C; Bezzi M; Manfredi R
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5343-5350. PubMed ID: 31298386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.
    Peskov K; Azarov I; Chu L; Voronova V; Kosinsky Y; Helmlinger G
    Front Immunol; 2019; 10():924. PubMed ID: 31134058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to: "Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures".
    Hickey RM
    J Vasc Interv Radiol; 2018 Apr; 29(4):587. PubMed ID: 29579466
    [No Abstract]   [Full Text] [Related]  

  • 9. Cross-sectional study of the provision of interventional oncology services in the UK.
    Zhong J; Atiiga P; Alcorn DJ; Kay D; Illing R; Breen DJ; Railton N; McCafferty IJ; Haslam PJ; Wah TM
    BMJ Open; 2017 Oct; 7(10):e016631. PubMed ID: 29061610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventional oncology research in the United States: slowing growth, limited focus, and a low level of funding.
    Chow DS; Itagaki MW
    Radiology; 2010 Nov; 257(2):410-7. PubMed ID: 20829537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.
    Huang X; Tsauo J; Zhao H; Li X
    J Vasc Interv Radiol; 2018 Apr; 29(4):586. PubMed ID: 29579465
    [No Abstract]   [Full Text] [Related]  

  • 12. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.
    Hickey RM; Kulik LM; Nimeiri H; Kalyan A; Kircher S; Desai K; Riaz A; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2017 Nov; 28(11):1487-1494. PubMed ID: 28912090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Musculoskeletal interventional oncology: current and future practices.
    Cazzato RL; Garnon J; Koch G; Dalili D; Rao PP; Weiss J; Bauones S; Auloge P; de Marini P; Gangi A
    Br J Radiol; 2020 Nov; 93(1115):20200465. PubMed ID: 32783618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.
    Erinjeri JP; Fine GC; Adema GJ; Ahmed M; Chapiro J; den Brok M; Duran R; Hunt SJ; Johnson DT; Ricke J; Sze DY; Toskich BB; Wood BJ; Woodrum D; Goldberg SN
    Radiology; 2019 Jul; 292(1):25-34. PubMed ID: 31012818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.
    Lin YM; Taiji R; Calandri M; Odisio BC
    Curr Oncol Rep; 2021 Apr; 23(6):67. PubMed ID: 33855606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy.
    Mehra R; Huang H; Seal B; Tse J; Shenolikar RA; Burudpakdee C
    Head Neck; 2020 Aug; 42(8):2030-2038. PubMed ID: 32149458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement.
    Tsimberidou AM; Levit LA; Schilsky RL; Averbuch SD; Chen D; Kirkwood JM; McShane LM; Sharon E; Mileham KF; Postow MA
    J Clin Oncol; 2019 Jan; 37(1):72-80. PubMed ID: 30339040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Master protocols in immuno-oncology: do novel drugs deserve novel designs?
    Mazzarella L; Morganti S; Marra A; Trapani D; Tini G; Pelicci P; Curigliano G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32238471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interventional oncology and immuno-oncology : Status quo].
    Helmberger T
    Radiologe; 2020 Aug; 60(8):681. PubMed ID: 32748259
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
    Hepp Z; Shah SN; Smoyer K; Vadagam P
    J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.